

**IMPROVED VASCULAR ENGRAFTMENT AND GRAFT FUNCTION  
FOLLOWING INHIBITION OF THE ANGIOSTATIC FACTOR  
THROMBOSPONDIN-1 IN MOUSE PANCREATIC ISLETS**

Johan Olerud<sup>1</sup>, Magnus Johansson<sup>1</sup>, Jack Lawler<sup>2</sup>, Nils Welsh<sup>1</sup>, and Per-Ola Carlsson<sup>1,3</sup>

<sup>1</sup>Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.

<sup>2</sup>Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School,  
Boston, MA, USA

<sup>3</sup>Department of Medical Sciences, Uppsala University, Uppsala, Sweden

**Address correspondence to:**  
Per-Ola Carlsson, MD, PhD.  
Department of Medical Cell Biology  
Uppsala University  
Husargatan 3, Box 571  
SE-751 23 Uppsala, Sweden  
e-mail: Per-Ola.Carlsson@mcb.uu.se

Abbreviations:

AUC; area under the curve  
BS-1; *Bandeiraea simplicifolia*  
BSA; bovine serum albumin  
FCS; Fetal calf serum  
PBS; phosphate buffered saline  
siRNA; small interfering ribonucleic acid  
TPU; tissue perfusion units  
TSP-1; thrombospondin-1  
VEGF; vascular endothelial growth factor

Received for publication 28 May 2007 and accepted in revised form 10 April 2008.

**Objective:** Insufficient development of a new intra-islet capillary network following transplantation may be one contributing factor to the failure of islet grafts in clinical transplantation. The present study tested the hypothesis that the angiostatic factor thrombospondin-1 (TSP-1), which is normally present in islets, restricts intra-islet vascular expansion posttransplantation.

**Research Design and Methods:** Pancreatic islets of TSP-1 deficient (TSP-1 (-/-)) mice, or wild-type islets transfected with siRNA for TSP-1, were transplanted beneath the renal capsule of syngeneic or immunocompromised recipient mice.

**Results:** Both genetically TSP-1 (-/-) islets and TSP-1 siRNA-transfected islet cells demonstrated an increased vascular density when compared to control islets one month following transplantation. This was also reflected in a markedly increased blood perfusion and oxygenation of the grafts. The functional importance of the improved vascular engraftment was analyzed by comparing glucose-stimulated insulin release from islet cells transfected with either TSP-1 siRNA or scramble siRNA prior to implantation. These experiments showed that the increased revascularization of grafts composed of TSP-1 siRNA-transfected islet cells correlated to increments in both their first and second phase of glucose-stimulated insulin secretion.

**Conclusions:** Our findings demonstrate that inhibition of TSP-1 in islets intended for transplantation may be a feasible strategy to improve islet graft revascularization and function.

Despite improvements in immunosuppression protocols over the last years, pancreatic islets from at least two donor pancreata are still needed to reverse type 1 diabetes in clinical islet transplantation (1; 2). This is far more than the alleged 10-20% of the total islet volume suggested to be enough to maintain normoglycemia in humans. Moreover, in contrast to the results for whole organ transplantation, there seems to be a continuous decline in islet graft function, and very few patients remain insulin-independent at five years posttransplantation (2; 3). Since the histocompatibility barrier, the underlying autoimmune disease, and the immunosuppressive agents used are the same for both transplantation procedures, it is likely that issues related to the adaptation of the implanted islets to their new microenvironment play a role for the differences in results.

Pancreatic islets become disconnected from their vascular supply during collagenase digestion prior to transplantation. Revascularization of transplanted islets has been shown to be concluded within 7-14 days (4). However, the resulting vascular density remains lower than in endogenous islets (5-7) and is associated with an impaired oxygenation (6; 8) and endocrine function (7; 9; 10).

We have recently observed that freshly isolated rodent islets become better revascularized and function better than islets cultured for several days before transplantation (11), although the islet vascular system, also when using freshly isolated islets for transplantation, is far from fully restored. One possible explanation for the improved vascular engraftment in such islets is that not only host blood vessels, but also remnant donor islet endothelial cells, may participate in the formation of a new islet vascular network (12-14). However, despite

the presence of several mitogens for endothelial cells within the islets, such as vascular endothelial growth factor (VEGF), fibroblast growth factor and matrix metalloproteinases (15-17), intra-islet endothelial cells normally have a very low proliferation rate (18; 19). This endothelial quiescence is presumably due to the fact that proangiogenic factors normally are counteracted by antiangiogenic factors present in the islets (20), including the islet endothelial cells themselves (21; 22). A possible key factor in this context is thrombospondin-1 (TSP-1), since it is not downregulated by hypoxia (20), which occur posttransplantation. Moreover, animals deficient of this glycoprotein are characterized by hypervascular islets (23). The present study tested the hypothesis that use of genetically TSP-1 (-/-) islets, or transfection of islets in vitro with siRNA for TSP-1, would create a microenvironment permissive for blood vessel growth within islets and improve vascular engraftment and function following transplantation.

## **RESEARCH DESIGN AND METHODS**

**Animals.** Pancreatic islets from wild-type (TSP-1 (+/+)), heterozygous TSP-1 (+/-) and TSP-1 (-/-) C57BL/6 mice of the F2-F3 generations were used for transplantation. The TSP-1 (-/-) mice were generated by homologous recombination in 129/Sv-derived ES cells implanted in C57BL/6 blastocysts (24). A breeding program of such mice was established at Uppsala University, and male mice 10-12 weeks of age were allocated to the studies. Age-matched wild-type male C57BL/6 mice were used as controls. Recipient C57BL/6 (nu/nu) mice, weighing approximately 30g, were purchased from M&B Research and Breeding Center (Ry, Denmark). For experiments with siRNA, adult, inbred, C57BL/6 mice (M&B) were

used both as islet donors and recipients. All animals had free access to water and food throughout the course of the study. The experiments were approved by the animal ethics committee for Uppsala University.

**Islet isolation and culture.** Islets from wild-type, TSP-1 (+/-) and TSP-1 (-/-) C57BL/6 mice were prepared by collagenase digestion (25), and cultured at 37°C free-floating in 5 ml culture medium composed of RPMI 1640 medium (Sigma-Aldrich, Irvine, UK) to which we added 11 mmol/l glucose, 10% (vol/vol) fetal calf serum (FCS; Sigma-Aldrich), 0.17 mmol/l sodium benzylpenicillate, and 0.17 mmol/l streptomycin.

**TSP-1 siRNA transfection of islet cells.** siRNA transfection was performed as previously described (26). Freshly isolated islets were dispersed at 37°C into single cells by addition of 5 mg/ml trypsin (Sigma-Aldrich) for <5 min. The trypsination was terminated with Ca<sup>2+</sup>-containing culture medium (RPMI-1640), followed by DNase I treatment [Amersham Life Science, Piscataway, NJ] (33mU/μl) for 1-2 min. The dispersed cells were washed in RPMI 1640 (Sigma-Aldrich) and divided into two equal fractions. Non-adhesive culture dishes were pretreated with FCS for 30 min at room temperature and then washed with RPMI 1640. Each fraction was placed into a non-adhesive culture dish followed by transfection with 100 nmol/l scramble- or an equal mixture of four different TSP-1 siRNA sequences (Table 1) using 10μg/600μl Lipofectamine® (Invitrogen, Lidingö, Sweden) in 600 μl RPMI 1640. Using this Lipofectamine® protocol, we have previously observed uptake of siRNA in >90% of all islet cells (26). After three hours the transfection medium was replaced with culture medium. The dispersed islets were reaggregated with a shaker over night at standard culture conditions before transplantation.

**TSP-1 mRNA expression analysis.**

Dispersed islet cells transfected with scramble- or TSP-1 siRNA, or freshly isolated islets were washed with phosphate buffered saline (PBS) followed by total RNA isolation using Ultraspec® (Biotech Laboratories, Houston, Texas). cDNA synthesis was performed with random nonamers (Sigma-Aldrich) and reverse transcriptase M-MuLV H<sup>-</sup> (Finnzymes, Espoo, Finland). Amplification was obtained with a Lightcycler system (Roche-Diagnostic, Lewes, UK) using DyNAmo™ Capillary SYBR® Green qPCR Kit (Finnzymes). β-actin was used as house keeping gene. For primer sequences used, see Table 1.

**TSP-1 protein expression analysis.**

Whole islets, kidney and spleen homogenates, as well as dispersed islet cells transfected with scramble or TSP-1 siRNA and incubated 1-7 days, were washed in cold PBS following lyses in SDS sample buffer (2% SDS; 0.15 mol/l Tris pH 8.8; 10% glycerol; 5% β-mercaptoethanol; bromophenol blue; 2 mmol/l phenylmethylsulfonylfluoride), boiled for 2 min, and separated on a 6 % SDS-PAGE gel. Proteins were transferred to Hypond™-P membrane (GE Healthcare, Uppsala, Sweden). The membranes were blocked in 2.5% bovine serum albumin (BSA) at 4°C over night followed by incubation with TSP-1 (Ab-2, Ab-4 Labvision, Fremont, CA; TX-17.10 Santa Cruz, Santa Cruz, CA) and HSP60 antibodies (Stressgen, Ann Arbor, MI) and probed with horseradish peroxidase antibody. The bound antibodies were visualized with Kodak image station 4000MM (Kodak, New Haven, CT) using ECL<sup>+</sup> (GE-Healthcare). The band intensities were calculated using Kodak Molecular imaging software 4.5.1 SE.

**Glucose-stimulated insulin release.**

Dispersed islet cells transfected with scramble or TSP-1 siRNA were reaggregated over night, cultured for 72h and investigated for glucose-stimulated insulin release and insulin

content. Groups of islet cells from 10 islets were transferred in triplicates to glass vials containing 250  $\mu$ l Krebs-Ringer bicarbonate buffer supplemented with 10 mmol/l HEPES (Sigma-Aldrich) and 2 mg/ml BSA (ICN Biomedicals, Aurora, OH); the buffer is hereafter referred to as KRBH buffer. The KRBH-buffer contained 1.67 mmol/l D-glucose during the first hour of incubation at 37°C ( $O_2:CO_2=95:5$ ). The medium was removed and replaced by 250  $\mu$ l KRBH supplemented with 16.7 mmol/l glucose and incubated for a second hour. The medium was again removed, and the islet cells harvested and homogenized in 200  $\mu$ l redistilled water. The aqueous homogenate were then used for DNA measurements by fluorophotometry (PicoGreen dsDNA Quantitation Kit, Molecular Probes, Eugene, OR). A fraction of the homogenate was mixed with acid-ethanol (0.18 mol/l HCL in 95% (vol/vol) ethanol) from which insulin was extracted over night at 4°C. Insulin contents in incubation media and homogenates were determined by ELISA (Mercodia, Uppsala, Sweden).

**Islet transplantation.** Groups of 250 wild-type, TSP-1 (+/-) or TSP-1 (-/-) C57BL/6 islets cultured for 3-4 days, or reaggregated scramble or TSP-1 siRNA transfected C57BL/6 islet cells, were packed in a braking pipette and syngeneically implanted beneath the capsule of the left kidney in non-diabetic C57BL/6 nu/nu mice anesthetized with avertin [2.5% (vol/vol) solution of 10 g 97% (vol/vol) 2,2,2-tribromoethanol (Sigma-Aldrich) in 10 ml 2-methyl-2-butanol] (Kemila, Stockholm, Sweden). For the transfected material, all reaggregated islet cells, irrespective of the size of the organoids, were transplanted.

**Measurements of blood flow and oxygen tension in transplanted islets.** One month posttransplantation the animals were anesthetized with avertin (cf. above), placed on a heated operating table (38°C) and tracheostomized. Polyethylene catheters were

inserted into the right carotid artery and left jugular vein. The former catheter was connected to a Statham P23dB pressure transducer (Statham Laboratories, Los Angeles, CA) to monitor arterial blood pressure, whereas the latter catheter was used for continuous infusion of Ringer solution (5 ml  $\times$  kg<sup>-1</sup>  $\times$  h<sup>-1</sup>) to substitute for loss of body fluid.

Following a left subcostal flank incision the graft-bearing left kidney was immobilized in a plastic cup. The kidney was embedded in cotton wool soaked in Ringer solution and covered with mineral oil (Apoteket, Gothenburg, Sweden) to prevent evaporation and keep the tissue moist at body temperature. The blood perfusion of the islet graft and the adjacent renal cortex was measured by laser-Doppler flowmetry (PF 4001-2 Perimed, Stockholm, Sweden). The laser-Doppler probe (outer tip diameter 0.45 mm) was positioned perpendicular to the immobilized tissue surface by the use of a micromanipulator, and care was taken not to cause any compression of the tissue. At least three blood flow measurements were performed in the transplanted islets and renal cortex in each animal. The mean of these measurements from each animal was calculated and considered to be one experiment. Since it is difficult to calibrate the instrument in physical units of blood flow, all blood flow values are given as arbitrary tissue perfusion units (TPU).

Oxygen tension was measured in the islet graft and the adjacent renal parenchyma with Clark microelectrodes (Unisense, Arhus, Denmark), as described in detail elsewhere (27; 28). The electrodes (outer tip diameter 2-6  $\mu$ m) were inserted into the tissues by the use of a micromanipulator under a stereo microscope. At least 10 measurements were performed in both the islet graft and the renal cortex. The mean of all measurements, in each tissue and animal, was calculated and considered to be one experiment. During the

blood flow and oxygen tension measurements, blood pressure, body temperature and tissue temperature were continuously monitored with a MacLab Instrument (AD Instruments, Hastings, UK). A mean arterial blood pressure <75 mm Hg was used as a pre-set exclusion criteria from the study.

**Measurements of blood parameters.** Blood glucose concentrations were determined with test reagent strips (Medisense; Baxter Travenol, Deerfield, IL) from samples obtained from the cut tip of the tail. At the end of blood flow and oxygen tension measurements, a blood sample was collected for analysis of hematocrit and blood gases. Animals with pH <7.30, pO<sub>2</sub><10 kPa, pCO<sub>2</sub>>6.8 kPa, or hematocrit <40 were excluded from the study.

**Light microscopic evaluation.** The graft-bearing kidneys were removed following the oxygen tension and blood flow measurements, fixed in 10% (vol/vol) formaldehyde and embedded in paraffin. Consecutive sections (5 µm thick) of the islet grafts were prepared and stained with the lectin *Bandeiraea Simplicifolia* (BS-1) or a monoclonal guinea pig anti-insulin antibody (ICN Biomedicals), as previously described (5), and counterstained with hematoxylin. In each case, ≥10 tissue sections stained with BS-1 or for insulin from all parts of the islet transplants were randomly chosen and evaluated. The blood vessel density and beta-cell percentage in pancreatic islets was determined by a direct point-counting method (29). For this purpose, a grid with 121 intersections were placed onto each tissue section under a light microscope (BS-1, 400X; insulin 1000X) (19). The number of intersections overlapping endothelial cells (stained with BS-1) or insulin-positive cells was then counted by an examiner unaware of the origin of the samples.

**Evaluation of islet graft function.** Grafts from some of the animals transplanted with

scramble or TSP-1 siRNA-transfected wild-type islet cells were investigated one month posttransplantation for glucose-stimulated insulin secretion as previously described (30). Briefly, the graft-bearing left kidney was removed together with a part of the aorta and inferior vena cava. The ureter and the renal vein were cut, while the aorta was cannulated and infused with a continuously gassed (O<sub>2</sub>:CO<sub>2</sub>=95:5) Krebs-Ringer bicarbonate buffer supplemented with 2.0% (wt/vol) of each of BSA (fraction V; Miles Laboratories, Slough, U.K.) and dextran T70 (Pharmacia, Uppsala, Sweden). At different times during the perfusion the medium contained either 2.8 or 16.7 mmol/l D-glucose. The medium was administered at a rate of 1 ml/min without recycling for 60 min with a perfusion pressure of approximately 40 mmHg. The perfusion experiments started with a 15-min period using medium containing 2.8 mmol/l glucose, which was followed by 30 min using 16.7 mmol/l glucose. The perfusions were concluded by a 15-min perfusion with medium containing 2.8 mmol/l glucose. A 1.0 ml sample was collected at min 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 35, 40, 45, 50, 55, 60. The insulin concentrations of the effluent samples were measured by ELISA (Merckodia). The rate of insulin secretion was calculated by multiplying the insulin concentration in the sample by the flow rate, giving values of insulin expressed as ng/min. The area under the curve (AUC) was then determined from these values.

**Statistical analysis.** Values are expressed as the mean±SEM. For comparisons of non-parametric data Wilcoxon Sign Rank test was used for comparisons between two groups, and Kruskal-Wallis test for multiple comparisons. When two groups of parametric data were compared, Student's paired or unpaired two-tailed t-test was used. For all comparisons, *P*-values <0.05 were considered statistically significant.

## RESULTS

**Animal characteristics.** All recipient mice allocated to the study weighed approximately 30 g at transplantation and had increased 5-10% in body weight when investigated one month later. Both donors of islets, including the TSP-1 (-/-) mice, and recipients were normoglycemic with non-fasting blood glucose concentrations of  $\sim 7$  mmol/l. All animals allocated to blood flow and oxygen tension measurements had a mean arterial blood pressure of 90-100 mm Hg. No animals had to be excluded based on the pre-set exclusion criteria for blood gases and hematocrit. However, two animals were excluded from studies of islet graft blood flow and oxygen tension due to hypotension (mean arterial blood pressure  $< 75$  mmHg) following perioperative bleeding.

**Expression of TSP-1 in different organs.** TSP-1 immunoreactivity was observed as a double band. When compared to spleen, pancreatic islets and kidneys contained low amounts of the protein TSP-1 (Fig 1A).

**Expression of TSP-1 mRNA and protein in islet cells following siRNA transfection.** Dispersed islet cells transfected with TSP-1 siRNA showed a  $\sim 40\%$  reduction in TSP-1 mRNA expression compared with dispersed islet cells transfected with scramble siRNA when evaluated 24 h posttransfection (Fig 1B). At the protein expression level, the effects of TSP-1 siRNA transfection caused a delayed effect, with an approximate 40% decrease first after one week (Fig 1C-D).

**Effects of TSP-1 siRNA transfection on islet function.** There were no differences in either insulin release at low glucose ( $50,2 \pm 5,5$  ng x  $\mu\text{g DNA}^{-1}$  x  $\text{h}^{-1}$  vs.  $47,2 \pm 6,7$  ng x  $\mu\text{g DNA}^{-1}$  x  $\text{h}^{-1}$ ) or high glucose concentrations ( $203,0 \pm 18,8$  ng x  $\mu\text{g DNA}^{-1}$  x  $\text{h}^{-1}$  vs.  $187,2 \pm 19,3$  ng x  $\mu\text{g DNA}^{-1}$  x  $\text{h}^{-1}$ ), or in islet insulin content ( $8,2 \pm 0,1$  ng/ng DNA vs  $7,5 \pm 0,3$  ng/ng DNA) between islet cells transfected with scramble siRNA or TSP-1 siRNA 72h prior to measurements.

**Blood flow.** One month posttransplantation, the blood perfusion of grafts composed of wild-type control islets or scramble siRNA-transfected islet cells were similar, and 40-50% of that in the adjacent renal cortex (Figs 2A and B, respectively). In comparison, grafts composed of islet tissue either genetically decreased or deficient in TSP-1 (Fig 2A), or transfected with siRNA for TSP-1 (Fig 2B), had a markedly higher blood perfusion when compared to their corresponding control.

**Oxygen tension.** The  $\text{pO}_2$  levels in islet grafts composed of wild-type control islets (Fig 3A), or in islet cells transfected with scramble siRNA prior to transplantation (Fig 3B), were 7-8 mmHg one month posttransplantation. Improved oxygenization compared to this was observed in islet grafts composed of either TSP-1 (+/-) islets, TSP-1 (-/-) islets, or islet cells transfected with TSP-1 siRNA before transplantation (Figs 3A and B, respectively).

**Vascular density.** Both wild-type control islets (Figs 4A, B) and scramble siRNA-transfected islets tissue (Figs 4D, E) had a blood vessel density of  $\sim 7\%$  one month posttransplantation. By contrast, both TSP-1 (-/-) islets (Figs 4A, C) and islet tissue transfected with siRNA for TSP-1 (Figs 4D, F) had an  $\sim 40\%$  increase in vascular density. Islet grafts composed of TSP-1 (+/-) islets had a vascular density in-between wild-type islet grafts and TSP-1 (-/-) islet grafts (Fig 4A). The increase in blood vessels numbers seemed to occur both in the center and peripheral regions of the TSP-1 (-/-) islets and TSP-1 siRNA transfected islet tissue.

**Islet transplant cell composition.** There were similar percentage beta-cells in grafts composed of wild-type islets or TSP-1 (-/-) islets ( $84.7 \pm 1.3\%$  (n=4) vs.  $86.2 \pm 0.9\%$  (n=5), respectively). Likewise, there was no difference in beta-cell percentage in the islet tissue composed of scramble siRNA transfected and TSP-1 siRNA transfected islet cells at one month follow-up ( $85.1 \pm 0.5\%$  vs.  $86.9 \pm 1.3\%$ , respectively).

**Islet graft function.** Perfusions of islet-graft bearing kidneys one month posttransplantation showed that islet tissue transfected with siRNA for TSP-1 had an improved both first and second peak of insulin release when compared to scramble siRNA-transfected islet cells (Figs 5A-C). Total AUC for glucose-stimulated insulin release in the TSP-1 siRNA-transfected islet tissue was thus increased by approximately 40% (Fig 5D).

## DISCUSSION

Adult pancreatic islets have a dense glomerular-like angioarchitecture that requires VEGF-signaling from the beta-cells for its formation and maintenance (31-34). However, despite chronic exposure to VEGF vascular expansion does not normally occur in islets after the first postnatal week (35). Likewise, although increased amounts of not only VEGF, but also other proangiogenic factors such as hepatocyte growth factor, are secreted from newly transplanted islets (16; 36), new blood vessel formation within the islets also during these conditions is sparse (5-7). Instead, a rich vascular network is formed in the stroma around each single transplanted islet (5). This suggests the presence of matrix- or tissue-bound angiostatic factors within the implanted islets that prevent intra-islet vascular formation. Marked overexpression of VEGF in the donor tissue has previously been shown in experimental studies to overcome this and improve islet graft revascularization and function (9; 10). However, silencing some of the angiostatic factors may be an even simpler strategy.

In this study we tested the hypothesis that un-opposing the action of already present pro-angiogenic factors through silencing TSP-1 in islets would improve islet graft revascularization and function. The glycoprotein TSP-1 binds to the extracellular matrix (37; 38), and exerts its main effects

through inducing apoptosis selectively in activated endothelial cells, i.e. those that are forming new blood vessels, but not quiescent endothelium (39). It also inhibits angiogenesis by blocking the mobilisation of pro-angiogenic factors such as matrix metalloproteinase-9 (MMP-9) and VEGF, and by inhibiting their access to co-receptors on the endothelial cell surface (40).

We investigated the influence of TSP-1 on islet graft revascularization using two different models: by transplanting genetically TSP-1 deficient islets, and by transplanting islet cells transfected with siRNA for TSP-1 *in vitro* prior to transplantation. The first model thereby provides a persistent partial (TSP-1 (+/-)) or complete loss (TSP-1 (-/-)) of TSP-1 expression in the islets, whereas the latter causes only a transient decrease in TSP-1 levels. Using both approaches, we observed a markedly improved vascular engraftment of the transplanted islets with improved intra-islet vascular density at one month follow-up. In both models, the newly formed blood vessels also seemed to be functional, since the improved vascular density was reflected in an increased blood perfusion and pO<sub>2</sub> in the islet grafts. Notably, the pO<sub>2</sub> increase was especially prominent in the TSP-1 (-/-) mice, where TSP-1 expression is chronically deficient, and of a greater magnitude than the increase in blood vessel numbers. It is possible that this reflects higher blood perfusion in individual blood vessels and thereby better oxygen transport capacities of islet blood vessels in the absence of TSP-1 e.g. due to loss of the previously described counteracting effect of TSP-1 on nitric oxide mediated vasodilation (41). Nitric oxide is the main mediator of high blood perfusion in endogenous and transplanted islets (42; 43). It should be noted that an intra-islet vasodilation is not necessarily reflected in increased total graft blood flow, which is measured by laser-Doppler flowmetry, since total graft blood flow represents not only the nutritive blood

flow to the endocrine cells, but also blood flow in the vast number of stroma capillaries. In contrast, it could be expected that the blood flow in capillaries in the endocrine parts mainly contributes to the delivery of oxygen to the endocrine cells due to limitations of oxygen diffusion (44).

In our characterization of TSP-1 (-/-) mice, we observed that these mice had fasting and non-fasting blood glucose levels that were normal and did not differ from those of wild-type animals. However, despite that TSP-1 (-/-) mice have been described to have an increased islet mass (23), closer investigations revealed that these animals were slightly glucose intolerant and had a decreased islet function (45), which probably reflects the role of TSP-1 in transforming growth factor- $\beta_1$  activation (23). Nevertheless, we hypothesized that a transient decrease in islet TSP-1 levels during the acute revascularization phase of transplanted islets may still be beneficial for long-term islet function, considering that such a decrease also can be seen physiologically during the islet vascular expansion of pregnant rats. In our protocol for TSP-1 siRNA transfection of islet cells using Lipofectamine® as vector, there was a transient decrease in islet TSP-1 levels both at the mRNA and protein level of a similar magnitude as seen in islets during pregnancy, i.e. ~40%. In rapidly dividing cells the silencing effect of siRNA usually lasts for less than 1 week, but up to 3-4 weeks in non-dividing cells both in vitro and in vivo (46). Probably due to the low proliferation rate of adult endocrine cells, including  $\beta$ -cells, and turn-over rate of the extracellular matrix binding of the TSP-1 protein, silencing of TSP-1 in these cells was manifested not until after one week at the protein level. A partial effect of TSP-1 siRNA may also be on the remnant donor islet endothelial cells, since also these cells contain TSP-1 (22). However, in this case the effect is probably much

shorter due to cell division as part of angiogenesis.

When graft function was evaluated by perfusion of graft-bearing kidneys one month posttransplantation, islet cells exposed to siRNA for TSP-1 prior to transplantation performed better than control islet cells exposed to scramble siRNA. The chosen model to evaluate graft function also enabled us to separately evaluate the effects of improved vascular engraftment on the insulin release kinetics from transplanted islets. It is noteworthy that the peak of the first phase of glucose-stimulated insulin secretion was substantially higher in the better revascularized islet grafts, which is similar to what we have previously observed when improving blood perfusion, but not revascularization, by angiotensin II receptor inhibition (47). However, in contrast to when only the blood perfusion was improved, we observed in the present study also an augmented second phase of glucose-stimulate insulin secretion. This suggests that the present findings do not merely reflect a “wash-out” effect of insulin retained in the islet grafts due to low blood perfusion. The general improvement of glucose-stimulated insulin release may instead reflect an improved survival, a better oxygenation and/or a better endothelial paracrine support of the islet beta-cells. The normally low oxygenation of transplanted islets may affect islet survival and function, since it means that their metabolism tends to be much more anaerobic than that of endogenous islets and result in lactate formation and tissue acidosis (48). Several recent reports also indicate that endothelial cell signalling may be important for beta-cell function and growth (19; 49; 50).

We conclude that transient inhibition of TSP-1 early posttransplantation may be used to improve islet graft revascularization and function. Such a strategy, e.g. by development of pharmacological inhibitors, may be more feasible in the clinical setting than trying to

increase the expression of pro-angiogenic factors in the transplanted tissue even further.

### **ACKNOWLEDGEMENTS**

The skilled technical assistance of Astrid Nordin, Birgitta Bodin and Eva Törnelli is gratefully acknowledged. This work was

supported by grants from The Swedish Research Council (55X-15043), The Juvenile Diabetes Research Foundation, the EFSD/JDRF/Novo Nordisk Research Programme 2006, The Swedish Diabetes Association, The Swedish Juvenile Diabetes Fund, The Anér Foundation and The Family Ernfors Fund.

## REFERENCES

1. Shapiro AM, Lakey JR, Ryan EA, Korbitt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N Engl J Med* 343:230-238, 2000
2. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM: Five-year follow-up after clinical islet transplantation. *Diabetes* 54:2060-2069, 2005
3. Humar A, Kandaswamy R, Granger D, Gruessner RW, Gruessner AC, Sutherland DE: Decreased surgical risks of pancreas transplantation in the modern era. *Ann Surg* 231:269-275, 2000
4. Menger MD, Jaeger S, Walter P, Feifel G, Hammersen F, Messmer K: Angiogenesis and hemodynamics of microvasculature of transplanted islets of Langerhans. *Diabetes* 38 Suppl 1:199-201, 1989
5. Mattsson G, Jansson L, Carlsson PO: Decreased vascular density in mouse pancreatic islets after transplantation. *Diabetes* 51:1362-1366, 2002
6. Carlsson PO, Palm F, Mattsson G: Low revascularization of experimentally transplanted human pancreatic islets. *J Clin Endocrinol Metab* 87:5418-5423, 2002
7. Contreras JL, Smyth CA, Eckstein C, Bilbao G, Thompson JA, Young CJ, Eckhoff DE: Peripheral mobilization of recipient bone marrow-derived endothelial progenitor cells enhances pancreatic islet revascularization and engraftment after intraportal transplantation. *Surgery* 134:390-398, 2003
8. Carlsson PO, Palm F, Andersson A, Liss P: Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. *Diabetes* 50:489-495, 2001
9. Zhang N, Richter A, Suriawinata J, Harbaran S, Altomonte J, Cong L, Zhang H, Song K, Meseck M, Bromberg J, Dong H: Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. *Diabetes* 53:963-970, 2004
10. Lai Y, Schneider D, Kiszun A, Hauck-Schmalenberger I, Breier G, Brandhorst D, Brandhorst H, Iken M, Brendel MD, Bretzel RG, Linn T: Vascular endothelial growth factor increases functional beta-cell mass by improvement of angiogenesis of isolated human and murine pancreatic islets. *Transplantation* 79:1530-1536, 2005
11. Olsson R, Carlsson PO: Better vascular engraftment and function in pancreatic islets transplanted without prior culture. *Diabetologia* 48:469-476, 2005
12. Linn T, Schneider K, Hammes HP, Preissner KT, Brandhorst H, Morgenstern E, Kiefer F, Bretzel RG: Angiogenic capacity of endothelial cells in islets of Langerhans. *Faseb J* 17:881-883, 2003
13. Brissova M, Fowler M, Wiebe P, Shostak A, Shiota M, Radhika A, Lin PC, Gannon M, Powers AC: Intra-islet endothelial cells contribute to revascularization of transplanted pancreatic islets. *Diabetes* 53:1318-1325, 2004
14. Nyqvist D, Kohler M, Wahlstedt H, Berggren PO: Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts. *Diabetes* 54:2287-2293, 2005
15. Kuroda M, Oka T, Oka Y, Yamochi T, Ohtsubo K, Mori S, Watanabe T, Machinami R, Ohnishi S: Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. *J Clin Endocrinol Metab* 80:3196-3200, 1995
16. Vasir B, Reitz P, Xu G, Sharma A, Bonner-Weir S, Weir GC: Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-alpha, TGF-beta, bFGF and Vimentin) in cultured and transplanted rat islets. *Diabetologia* 43:763-772, 2000

17. Barro C, Zaoui P, Morel F, Benhamou PY: Matrix metalloproteinase expression in rat pancreatic islets. *Pancreas* 17:378-382, 1998
18. Lou J, Triponez F, Oberholzer J, Wang H, Yu D, Buhler L, Cretin N, Mentha G, Wollheim CB, Morel P: Expression of alpha-1 proteinase inhibitor in human islet microvascular endothelial cells. *Diabetes* 48:1773-1778, 1999
19. Johansson M, Mattsson G, Andersson A, Jansson L, Carlsson PO: Islet endothelial cells and pancreatic beta-cell proliferation: studies in vitro and during pregnancy in adult rats. *Endocrinology* 147:2315-2324, 2006
20. Tillmar L, Welsh N: In vitro cultured rat islets express genes that both prevent and promote angiogenesis. *Jop* 5:81-91, 2004
21. Mattsson G, Danielsson A, Kriz V, Carlsson PO, Jansson L: Endothelial cells in endogenous and transplanted pancreatic islets: differences in the expression of angiogenic peptides and receptors. *Pancreatol* 6:86-95, 2006
22. Cantaluppi V, Biancone L, Romanazzi GM, Figliolini F, Beltramo S, Ninniri MS, Galimi F, Romagnoli R, Franchello A, Salizzoni M, Perin PC, Ricordi C, Segoloni GP, Camussi G: Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. *Am J Transplant* 6:2601-2611, 2006
23. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N: Thrombospondin-1 is a major activator of TGF-beta1 in vivo. *Cell* 93:1159-1170, 1998
24. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO: Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. *J Clin Invest* 101:982-992, 1998
25. Andersson A: Isolated mouse pancreatic islets in culture: effects of serum and different culture media on the insulin production of the islets. *Diabetologia* 14:397-404, 1978
26. Hagerkvist R, Mokhtari D, Myers JW, Tengholm A, Welsh N: siRNA produced by recombinant dicer mediates efficient gene silencing in islet cells. *Ann N Y Acad Sci* 1040:114-122, 2005
27. Carlsson PO, Liss P, Andersson A, Jansson L: Measurements of oxygen tension in native and transplanted rat pancreatic islets. *Diabetes* 47:1027-1032, 1998
28. Revsbech PN: An oxygen microsensor with a guard cathode. *Limnol Oceanogr* 34:474-478, 1989
29. Weibel E: Practical methods for biological morphometry. In *Stereological Methods* Weibel E, Ed. London, Academic Press, 1979, p. 15
30. Korsgren O, Jansson L, Andersson A: Effects of hyperglycemia on function of isolated mouse pancreatic islets transplanted under kidney capsule. *Diabetes* 38:510-515, 1989
31. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. *Cancer Cell* 1:193-202, 2002
32. Brissova M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, Kantz J, Chen Z, Carr C, Jerome WG, Chen J, Baldwin HS, Nicholson W, Bader DM, Jetton T, Gannon M, Powers AC: Pancreatic islet production of vascular endothelial growth factor--a is essential for islet vascularization, revascularization, and function. *Diabetes* 55:2974-2985, 2006
33. Lammert E, Gu G, McLaughlin M, Brown D, Brekken R, Murtaugh LC, Gerber HP, Ferrara N, Melton DA: Role of VEGF-A in vascularization of pancreatic islets. *Curr Biol* 13:1070-1074, 2003

34. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM: VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. *Am J Physiol Heart Circ Physiol* 290:H560-576, 2006
35. Johansson M, Andersson A, Carlsson PO, Jansson L: Perinatal development of the pancreatic islet microvasculature in rats. *J Anat* 208:191-196, 2006
36. Vasir B, Jonas JC, Steil GM, Hollister-Lock J, Hasenkamp W, Sharma A, Bonner-Weir S, Weir GC: Gene expression of VEGF and its receptors Flk-1/KDR and Flt-1 in cultured and transplanted rat islets. *Transplantation* 71:924-935, 2001
37. Lawler J: Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. *J Cell Mol Med* 6:1-12, 2002
38. Armstrong LC, Bornstein P: Thrombospondins 1 and 2 function as inhibitors of angiogenesis. *Matrix Biol* 22:63-71, 2003
39. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. *Nat Med* 6:41-48, 2000
40. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. *Proc Natl Acad Sci U S A* 98:12485-12490, 2001
41. Isenberg JS, Wink DA, Roberts DD: Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. *Cardiovasc Res* 71:785-793, 2006
42. Svensson AM, Ostenson CG, Sandler S, Efendic S, Jansson L: Inhibition of nitric oxide synthase by NG-nitro-L-arginine causes a preferential decrease in pancreatic islet blood flow in normal rats and spontaneously diabetic GK rats. *Endocrinology* 135:849-853, 1994
43. Olsson R, Jansson L, Andersson A, Carlsson PO: Local blood flow regulation in transplanted rat pancreatic islets: influence of adenosine, angiotensin II, and nitric oxide inhibition. *Transplantation* 70:280-287, 2000
44. Dionne KE, Colton CK, Yarmush ML: Effect of oxygen on isolated pancreatic tissue. *ASAIO Trans* 35:739-741, 1989
45. Olerud J, Johansson M, Johansson Å, Welsh N, Carlsson P-O: Thrombospondin-1: produced by islet endothelial cells and crucial for beta-cell function. *Diabetic Medicine* 23 (Suppl 1):418A, 2006
46. Derek W, Bartlett, Davis ME: Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. *Nucleic Acids Research* 34:12, 2006
47. Kampf C, Lau T, Olsson R, Leung PS, Carlsson PO: Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts. *Diabetologia* 48:1159-1167, 2005
48. Carlsson PO, Nordin A, Palm F: pH is decreased in transplanted rat pancreatic islets. *Am J Physiol Endocrinol Metab* 284:E499-504, 2003
49. Nikolova G, Jabs N, Konstantinova I, Domogatskaya A, Tryggvason K, Sorokin L, Fassler R, Gu G, Gerber HP, Ferrara N, Melton DA, Lammert E: The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. *Dev Cell* 10:397-405, 2006
50. Johansson Å, Johansson M, Carlsson P-O: Islet endothelial cell signaling augment beta cell function. *Diabetologia* 49 (Suppl 1):317-318A, 2006

**Table 1: PCR primers and siRNA sequences**


<b>Gene/siRNA</b>	<b>Accession number</b>	<b>Primer/siRNA sequence (5'-3')</b>
	<b>GenBank</b>	<b>F=forward</b>
		<b>R=reverse</b>
$\beta$ -actin <sup>1</sup>	NM_007393	<b>F</b> GCTCTGGCTCCTAGCACC <b>R</b> GAGGAAGCAGTGGCGATACA
TSP-1 <sup>1</sup>	NM_011580	<b>F</b> GGAACGGAAAGACAACACTG <b>R</b> AGTTGAGCCCGGTCCTCTTG
Scramble siRNA <sup>2</sup>		CAGUCGCGUUUGCGACUGG
TSP-1 siRNA 1 <sup>3</sup>		GAUGACUACGCUGGCUUUGUU
TSP-1 siRNA 2 <sup>3</sup>		GCCUGCAAGAAAGACGCCUdTT
TSP-1 siRNA 3 <sup>3</sup>		CAAAGGCUGCUCCAGCUCUdTT
TSP-1 siRNA 4 <sup>3</sup>		CAAUCUGGACAACUGUCCcdTT

<sup>1</sup>Primers ordered from MWG Biotech, Ebersberg, Germany.


<sup>2</sup>Scramble siRNA sequence ordered from Dharmacon Research Inc, Chicago, USA.

<sup>3</sup>TSP-1 siRNA sequences ordered from Qiagen, Hilden, Germany.


FIGURES




**Figure 1.** Dispersed islet cells transfected with scramble or TSP-1 siRNA. (A) TSP-1 protein expression in C57Bl/6 mice tissues. Upper panel shows TSP-1 protein expression in spleen, kidney and freshly isolated islets. The lower panel shows the same filter stained with amido black for total protein loading. The figure is representative for 4 separate experiments. (B) TSP-1 mRNA expression 24 h posttransfection. Values are means $\pm$ SEM for 6-11 experiments in each group. Each experiment represents a paired comparison of scramble siRNA and TSP-1 siRNA transfection with islet cells isolated and pooled from 2 mice. Separate experiments with native expression of TSP-1 in freshly isolated whole islets are included as reference. \* denotes  $P=0,03$  for TSP-1 siRNA when compared to scramble siRNA transfection. (C) Islet cells were lysed and separated by SDS-PAGE 1, 3 and 7 days posttransfection. The figure shows TSP-1 and HSP60 (used as loading control) immunoreactivity on the same filter. (D) The TSP-1/HSP60 protein ratio from filters shown in panel C was analysed on day 1, 3 and 7 days after the transfection and is expressed as the TSP-1 siRNA/Scr siRNA ratio. \* denotes  $P=0.02$  when compared to scramble siRNA transfection from 4 separate experiments.




**Figure 2.** Blood flow in renal subcapsular islet grafts and adjacent renal cortex one month posttransplantation. In **(A)** the islet grafts were composed of 250 wild-type (black bars) or thrombospondin-1 (TSP-1) (+/-) (hatched bars) or TSP-1 (-/-) islets (open bars). \* denotes  $P \leq 0,003$  when compared to wild-type islets. # denotes  $P = 0,03$  when TSP-1 (-/-) was compared with TSP-1 (+/-). In **(B)** the islet grafts were composed of 250 scramble (black bars) or TSP-1 siRNA-transfected islets (open bars). \* denotes  $P = 0,04$  when compared to scramble siRNA transfected islets. Blood flow values are expressed as Tissue Perfusion Units (TPU). Values are means  $\pm$  SEM for 6 experiments in each group.



**Figure 3.** Oxygen tension in renal subcapsular islet grafts and adjacent renal cortex one month posttransplantation. In (A) the islet grafts were composed of 250 wild-type (black bars) or thrombospondin-1 (TSP-1) (+/-) (hatched bars) or TSP-1 (-/-) islets (open bars). In (B) the islet grafts were composed of 250 scramble (black bars) or TSP-1 siRNA-transfected islets (open bars). Values are means $\pm$ SEM for 6 experiments in each group. \* denotes  $P\leq 0,001$  when compared to control islets (black bars) in both A and B. # denotes  $P=0,003$  when TSP (-/-) was compared with TSP-1 (+/-).



**Figure 4.** Vascular density in renal subcapsular islet grafts one month posttransplantation. **(A)** Percentage of islet area constituted by blood vessels in islet grafts composed of wild-type (black bars), thrombospondin-1 (TSP-1 (+/-) (hatched bars), or TSP-1 (-/-) islets (open bars). \* denotes  $P=0,046$  when compared to wild-type islets. **(B, C)** Micrographs of islet grafts composed of wild-type **(B)** or TSP-1 (-/-) islets **(C)** stained with the endothelial marker *Bandeiraea simplicifolia* (red). **(D)** Percentage of islet area constituted by blood vessels in islet grafts composed of scramble (black bars) or TSP-1 siRNA-transfected islets (open bars). \* denotes  $P=0,016$  when compared to scramble siRNA transfected islets. **(E, F)** Micrographs of islet grafts composed of scramble **(E)** or TSP-1 siRNA-transfected islets **(F)**. Values in **A** and **D** are means $\pm$ SEM for 5-8 (A) and 4 experiments in each group, respectively. Scale bars in micrographs are 50  $\mu$ m.



**Figure 5.** Functional studies with perfusions of renal subcapsular islet grafts one month posttransplantation. (A) Insulin release in response to 16.7 mmol/l glucose (bar) from grafts composed of 250 scramble (closed circles) or TSP-1 siRNA-transfected islets (open circles). (B-D) Area under the curve (AUC) for the first phase (B) of glucose-stimulated insulin release (min 14-18; \* denotes  $P=0,006$  when compared with control), the second phase (C) of glucose-stimulated insulin release (min 19-50; \* denotes  $P=0,041$  when compared with control) and (D) both the first and second phase of insulin release (min 14-50; \* denotes  $P=0,025$  when compared to control). Values are means $\pm$ SEM for 6 experiments with all groups.